Melanoma and lymphocyte cell-specific targeting incorporated into a heat shock protein cage architecture

Chemistry and Biology

Volumn 13, Issue 2, 2006, Pages 161-170

  Flenniken, Michelle L ^a   Willits, Deborah A ^a   Harmsen, Ann L ^a   Liepold, Lars O ^a   Harmsen, Allen G ^a   Young, Mark J ^a   Douglas, Trevor ^a  

^a MONTANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; HEAT SHOCK PROTEIN; PRIMER DNA;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELL CULTURE; CELL SEPARATION; CHEMISTRY; CYTOLOGY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; IMMUNOLOGY; LYMPHOCYTE; MELANOMA; METHANOCOCCUS; MOUSE; NANOTECHNOLOGY; NUCLEOTIDE SEQUENCE; PATHOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS;

ANIMALS; ANTIGENS, CD4; BASE SEQUENCE; CELL SEPARATION; CELLS, CULTURED; DNA PRIMERS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FLOW CYTOMETRY; HEAT-SHOCK PROTEINS; LYMPHOCYTES; MELANOMA; METHANOCOCCUS; MICE; MICE, INBRED BALB C; MICROSCOPY, FLUORESCENCE; NANOTECHNOLOGY;

METHANOCALDOCOCCUS JANNASCHII; MIRIDAE;

EID: 32844469560     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2005.11.007     Document Type: Article

References (98)

1. J.W.M. Bulte, T. Douglas, S. Mann, R.B. Frankel, B.M. Moskowitz, R.A. Brooks, C.D. Baumgarner, J. Vymazal, and J.A. Frank Magnetoferritin: biomineralization as a novel approach in the design of iron oxide-based MR contrast agents Inv. Rad. 29 Suppl. 2 1993 S214 S216
2. J.W.M. Bulte, T. Douglas, S. Mann, R.B. Frankel, B.M. Moskowitz, R.A. Brooks, C.D. Baumgarner, J. Vymazal, M.-P. Strub, and J.A. Frank Magnetoferritin: characterization of a novel superparamagnetic MR contrast agent J. Magn. Reson. Imaging. 4 1994 497 505
3. T. Douglas, and M. Young Host-guest encapsulation of materials by assembled virus protein cages Nature 393 1998 152 155
4. M.L. Flenniken, L.O. Liepold, B.E. Crowley, D.A. Willits, M.J. Young, and T. Douglas Selective attachment and release of a chemotherapeutic agent from the interior of a protein cage architecture Chem. Commun. (Camb.) 2005 447 449
5. M.L. Flenniken, D.A. Willits, S. Brumfield, M.J. Young, and T. Douglas The small heat shock protein cage from Methanococcus jannaschii is a versatile nanoscale platform for genetic and chemical modification Nano Lett. 3 2003 1573 1576
6. A. Chatterji, L.L. Burns, S.S. Taylor, G.P. Lomonossoff, J.E. Johnson, T. Lin, and C. Porta Cowpea mosaic virus: from the presentation of antigenic peptides to the display of active biomaterials Intervirology 45 2002 362 370
7. M. Allen, D. Willits, J. Mosolf, M. Young, and T. Douglas Protein cage constrained synthesis of ferrimagnetic iron oxide nanoparticles Adv. Mater. 14 2002 1562 1565
8. M. Allen, D. Willits, M. Young, and T. Douglas Constrained synthesis of cobalt oxide nano-materials in the 12-subunit protein cage from Listeria innocua Inorg. Chem. 42 2003 6300 6305
9. T.M. Allen, and P.R. Cullis Drug delivery systems: entering the mainstream Science 303 2004 1818 1822
10. T. Douglas Biomimetic synthesis of nanoscale particles in organized protein cages S. Mann Biomimetic Approaches in Materials Science 1996 VCH Publishers New York 91 115
11. T. Douglas, M. Allen, and M. Young Self-assembling protein cage systems and applications in nanotechnology S.R. Fahnestock A. Steinbuchel Polyamides and Complex Proteinaceous Materials I, Volume 7 2002 Wiley-VCH Weinheim, Germany 517
12. T. Douglas, E. Strable, D. Willits, A. Aitouchen, M. Libera, and M. Young Protein engineering of a viral cage for constrained nano-materials synthesis Adv. Mater. 14 2002 415 418
13. T. Douglas, and M. Young Virus particles as templates for materials synthesis Adv. Mater. 11 1999 679 681
14. J.M. Hooker, E.W. Kovacs, and M.B. Francis Interior surface modification of bacteriophage MS2 J. Am. Chem. Soc. 126 2004 3718 3719
15. E. Gillitzer, D. Willits, M. Young, and T. Douglas Chemical modification of a viral cage for multivalent presentation Chem. Commun. (Camb.) 2002 2390 2391
16. M.T. Klem, D. Willits, D.J. Solis, A.M. Belcher, M. Young, and T. Douglas Bio-inspired synthesis of protein encapsulated copt nanoparticles Adv. Func. Mater. 15 2005 1489 1494
17. C. Mao, D.J. Solis, B.D. Reiss, S.T. Kottmann, R.Y. Sweeney, A. Hayhurst, G. Georgiou, B. Iverson, and A.M. Belcher Virus-based toolkit for the directed synthesis of magnetic and semiconducting nanowires Science 303 2004 213 217
18. E. Koivunen, B. Wang, and E. Ruoslahti Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins Biotechnology (N. Y.) 13 1995 265 270
19. Q. Wang, E. Kaltgrad, T.W. Lin, J.E. Johnson, and M.G. Finn Natural supramolecular building blocks: wild-type cowpea mosaic virus Chem. Biol. 9 2002 805 811
20. Q. Wang, T.W. Lin, J.E. Johnson, and M.G. Finn Natural supramolecular building blocks: cysteine-added mutants of cowpea mosaic virus Chem. Biol. 9 2002 813 819
21. Q. Wang, T.W. Lin, L. Tang, J.E. Johnson, and M.G. Finn Icosahedral virus particles as addressable nanoscale building blocks Angew. Chem. Int. Ed. 41 2002 459 462
22. M.A. Allen, L.O. Leipold, J.W.M. Bulte, G. Basu, H.A. Zywicke, J.A. Frank, M. Young, and T. Douglas Paramagnetic viral nanoparticles as potential high-relaxivity MRI contrast agents Magn. Reson. Med. 54 2005 807 812
23. I. Roy, T.Y. Ohulchanskyy, H.E. Pudavar, E.J. Bergey, A.R. Oseroff, J. Morgan, T.J. Dougherty, and P.N. Prasad Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: a novel drug-carrier system for photodynamic therapy J. Am. Chem. Soc. 125 2003 7860 7865
24. W. Arap, R. Pasqualini, and E. Ruoslahti Chemotherapy targeted to tumor vasculature Curr. Opin. Oncol. 10 1998 560 565
25. W. Arap, R. Pasqualini, and E. Ruoslahti Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model Science 279 1998 377 380
26. G.R. Braslawsky, M.A. Edson, W. Pearce, T. Kaneko, and R.S. Greenfield Antitumor activity of adriamycin (hydrazone-linked) immunoconjugates compared with free adriamycin and specificity of tumor cell killing Cancer Res. 50 1990 6608 6614
27. G.R. Braslawsky, K. Kadow, J. Knipe, K. McGoff, M. Edson, T. Kaneko, and R.S. Greenfield Adriamycin(hydrazone)-antibody conjugates require internalization and intracellular acid hydrolysis for antitumor activity Cancer Immunol. Immunother. 33 1991 367 374
28. I. Brigger, C. Dubernet, and P. Couvreur Nanoparticles in cancer therapy and diagnosis Adv. Drug Deliv. Rev. 54 2002 631 651
29. H.M. Ellerby, W. Arap, L.M. Ellerby, R. Kain, R. Andrusiak, G.D. Rio, S. Krajewski, C.R. Lombardo, R. Rao, and E. Ruoslahti Anti-cancer activity of targeted pro-apoptotic peptides Nat. Med. 5 1999 1032 1038
30. D.F. Emerich, and C.G. Thanos Nanotechnology and medicine Expert Opin. Biol. Ther. 3 2003 655 663
31. A. Fundaro, R. Cavalli, A. Bargoni, D. Vighetto, G.P. Zara, and M.R. Gasco Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats Pharmacol. Res. 42 2000 337 343
32. D. Hallahan, L. Geng, S. Qu, C. Scarfone, T. Giorgio, E. Donnelly, X. Gao, and J. Clanton Integrin-mediated targeting of drug delivery to irradiated tumor blood vessels Cancer Cell 3 2003 63 74
33. S.S. Jana, D.J. Bharali, P. Mani, A. Maitra, C.M. Gupta, and D.P. Sarkar Targeted cytosolic delivery of hydrogel nanoparticles into HepG2 cells through engineered Sendai viral envelopes FEBS Lett. 515 2002 184 188
34. K.A. Janes, P. Calvo, and M.J. Alonso Polysaccharide colloidal particles as delivery systems for macromolecules Adv. Drug Deliv. Rev. 47 2001 83 97
35. K.A. Janes, M.P. Fresneau, A. Marazuela, A. Fabra, and M.J. Alonso Chitosan nanoparticles as delivery systems for doxorubicin J. Control. Release 73 2001 255 267
36. P. Laakkonen, M.E. Akerman, H. Biliran, M. Yang, F. Ferrer, T. Karpanen, R.M. Hoffman, and E. Ruoslahti Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells Proc. Natl. Acad. Sci. USA 101 2004 9381 9386
37. P. Laakkonen, K. Porkka, J.A. Hoffman, and E. Ruoslahti A tumor-homing peptide with a targeting specificity related to lymphatic vessels Nat. Med. 8 2002 751 755
38. G.M. Lanza, X. Yu, P.M. Winter, D.R. Abendschein, K.K. Karukstis, M.J. Scott, L.K. Chinen, R.W. Fuhrhop, D.E. Scherrer, and S.A. Wickline Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis Circulation 106 2002 2842 2847
39. K. Muller, T. Nahde, A. Fahr, R. Muller, and S. Brusselbach Highly efficient transduction of endothelial cells by targeted artificial virus-like particles Cancer Gene Ther. 8 2001 107 117
40. K. Na, E.S. Lee, and Y.H. Bae Adriamycin loaded pullulan acetate/sulfonamide conjugate nanoparticles responding to tumor pH: pH-dependent cell interaction, internalization and cytotoxicity in vitro J. Control. Release 87 2003 3 13
41. K. Na, and Y.H. Bae Self-assembled hydrogel nanoparticles responsive to tumor extracellular pH from pullulan derivative/sulfonamide conjugate: characterization, aggregation, and adriamycin release in vitro Pharm. Res. 19 2002 681 688
42. T. Nahde, K. Muller, A. Fahr, R. Muller, and S. Brusselbach Combined transductional and transcriptional targeting of melanoma cells by artificial virus-like particles J. Gene Med. 3 2001 353 361
43. S.A. Wickline, and G.M. Lanza Nanotechnology for molecular imaging and targeted therapy Circulation 107 2003 1092 1095
44. S.A. Wickline, and G.M. Lanza Molecular imaging, targeted therapeutics, and nanoscience J. Cell. Biochem. Suppl. 39 2002 90 97
45. H.S. Yoo, K.H. Lee, J.E. Oh, and T.G. Park In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates J. Control. Release 68 2000 419 431
46. Y. Choi, T. Thomas, A. Kotlyar, M.T. Islam, and J.R. Baker Jr. Synthesis and functional evaluation of DNA-assembled polyamidoamine dendrimer clusters for cancer cell-specific targeting Chem. Biol. 12 2005 35 43
47. G.M. Dubowchik, S. Radia, H. Mastalerz, M.A. Walker, R.A. Firestone, H. Dalton King, S.J. Hofstead, D. Willner, S.J. Lasch, and P.A. Trail Doxorubicin immunoconjugates containing bivalent, lysosomally-cleavable dipeptide linkages Bioorg. Med. Chem. Lett. 12 2002 1529 1532
48. H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, and E. Holmgren Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N. Engl. J. Med. 350 2004 2335 2342
49. N. Jendreyko, M. Popkov, R.R. Beerli, J. Chung, D.B. McGavern, C. Rader, and C.F. Barbas 3rd Intradiabodies, bispecific, tetravalent antibodies for the simultaneous functional knockout of two cell surface receptors J. Biol. Chem. 278 2003 47812 47819
50. H.D. King, G.M. Dubowchik, H. Mastalerz, D. Willner, S.J. Hofstead, R.A. Firestone, S.J. Lasch, and P.A. Trail Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains J. Med. Chem. 45 2002 4336 4343
51. H.D. King, D. Yurgaitis, D. Willner, R.A. Firestone, M.B. Yang, S.J. Lasch, K.E. Hellstrom, and P.A. Trail Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: a novel method for increasing the potency of doxorubicin immunoconjugates Bioconjug. Chem. 10 1999 279 288
52. P.A. Trail, D. Willner, A.B. Bianchi, A.J. Henderson, M.D. TrailSmith, E. Girit, S. Lasch, I. Hellstrom, and K.E. Hellstrom Enhanced antitumor activity of paclitaxel in combination with the anticarcinoma immunoconjugate BR96-doxorubicin Clin. Cancer Res. 5 1999 3632 3638
53. P.A. Trail, D. Willner, S.J. Lasch, A.J. Henderson, R.S. Greenfield, D. King, M.E. Zoeckler, and G.R. Braslawsky Antigen-specific activity of carcinoma-reactive BR64-doxorubicin conjugates evaluated in vitro and in human tumor xenograft models Cancer Res. 52 1992 5693 5700
54. V. Cortez-Retamozo, N. Backmann, P.D. Senter, U. Wernery, P. De Baetselier, S. Muyldermans, and H. Revets Efficient cancer therapy with a nanobody-based conjugate Cancer Res. 64 2004 2853 2857
55. S.O. Doronina, B.E. Toki, M.Y. Torgov, B.A. Mendelsohn, C.G. Cerveny, D.F. Chace, R.L. DeBlanc, R.P. Gearing, T.D. Bovee, and C.B. Siegall Development of potent monoclonal antibody auristatin conjugates for cancer therapy Nat. Biotechnol. 21 2003 778 784
56. J.A. Francisco, C.G. Cerveny, D.L. Meyer, B.J. Mixan, K. Klussman, D.F. Chace, S.X. Rejniak, K.A. Gordon, R. DeBlanc, and B.E. Toki cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity Blood 102 2003 1458 1465
57. I. Hellstrom, K.E. Hellstrom, and P.D. Senter Development and activities of the BR96-doxorubicin immunoconjugate Methods Mol. Biol. 166 2001 3 16
58. D. Willner, P.A. Trail, S.J. Hofstead, H.D. King, S.J. Lasch, G.R. Braslawsky, R.S. Greenfield, T. Kaneko, and R.A. Firestone (6-Maleimidocaproyl) hydrazone of doxorubicin: a new derivative for the preparation of immunoconjugates of doxorubicin Bioconjug. Chem. 4 1993 521 527
59. C. Rader, S.C. Sinha, M. Popkov, R.A. Lerner, and C.F. Barbas 3rd Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst Proc. Natl. Acad. Sci. USA 100 2003 5396 5400
60. P.A. Trail, D. Willner, S.J. Lasch, A.J. Henderson, S. Hofstead, A.M. Casazza, R.A. Firestone, I. Hellstrom, and K.E. Hellstrom Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates Science 261 1993 212 215
61. D.L. Ludwig, D.S. Pereira, Z. Zhu, D.J. Hicklin, and P. Bohlen Monoclonal antibody therapeutics and apoptosis Oncogene 22 2003 9097 9106
62. P.C. Brooks, A.M. Montgomery, M. Rosenfeld, R.A. Reisfeld, T. Hu, G. Klier, and D.A. Cheresh Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels Cell 79 1994 1157 1164
63. P.C. Brooks, S. Stromblad, R. Klemke, D. Visscher, F.H. Sarkar, and D.A. Cheresh Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin J. Clin. Invest. 96 1995 1815 1822
64. C. Rader, M. Popkov, J.A. Neves, and C.F. Barbas 3rd Integrin alpha(v)beta3 targeted therapy for Kaposi's sarcoma with an in vitro evolved antibody FASEB J. 16 2002 2000 2002
65. K.C. Brown Hitting the target with bifunctional phage Chem. Biol. 11 2004 1033 1035
66. E. Ruoslahti RGD and other recognition sequences for integrins Annu. Rev. Cell Dev. Biol. 12 1996 697 715
67. E. Ruoslahti Targeting tumor vasculature with homing peptides from phage display Semin. Cancer Biol. 10 2000 435 442
68. E. Ruoslahti Specialization of tumour vasculature Nat. Rev. Cancer 2 2002 83 90
69. R. Pasqualini, and E. Ruoslahti Tissue targeting with phage peptide libraries Mol. Psychiatry 1 1996 423
70. R. Pasqualini, and E. Ruoslahti Organ targeting in vivo using phage display peptide libraries Nature 380 1996 364 366
71. W. Arap, W. Haedicke, M. Bernasconi, R. Kain, D. Rajotte, S. Krajewski, H.M. Ellerby, D.E. Bredesen, R. Pasqualini, and E. Ruoslahti Targeting the prostate for destruction through a vascular address Proc. Natl. Acad. Sci. USA 99 2002 1527 1531
72. D. Rajotte, and E. Ruoslahti Membrane dipeptidase is the receptor for a lung-targeting peptide identified by in vivo phage display J. Biol. Chem. 274 1999 11593 11598
73. E. Ruoslahti Antiangiogenics meet nanotechnology Cancer Cell 2 2002 97 98
74. M.E. Akerman, W.C. Chan, P. Laakkonen, S.N. Bhatia, and E. Ruoslahti Nanocrystal targeting in vivo Proc. Natl. Acad. Sci. USA 99 2002 12617 12621
75. F.M. de Groot, H.J. Broxterman, H.P. Adams, A. van Vliet, G.I. Tesser, Y.W. Elderkamp, A.J. Schraa, R.J. Kok, G. Molema, and H.M. Pinedo Design, synthesis, and biological evaluation of a dual tumor-specific motive containing integrin-targeted plasmin-cleavable doxorubicin prodrug Mol. Cancer Ther. 1 2002 901 911
76. J. Wermuth, S.L. Goodman, A. Jonczyk, and H. Kessler Stereoisomerism and biological activity of the selective and superactice αvβ3 integrin inhibitor cyclo(-RGDfV-) and its retro-inverso peptide J. Am. Chem. Soc. 119 1997 1328 1335
77. R. Pasqualini, E. Koivunen, and E. Ruoslahti A peptide isolated from phage display libraries is a structural and functional mimic of an RGD-binding site on integrins J. Cell Biol. 130 1995 1189 1196
78. M. Friedlander, P.C. Brooks, R.W. Shaffer, C.M. Kincaid, J.A. Varner, and D.A. Cheresh Definition of two angiogenic pathways by distinct alpha v integrins Science 270 1995 1500 1502
79. P.M. Winter, S.D. Caruthers, A. Kassner, T.D. Harris, L.K. Chinen, J.S. Allen, E.K. Lacy, H. Zhang, J.D. Robertson, and S.A. Wickline Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3- targeted nanoparticle and 1.5 tesla magnetic resonance imaging Cancer Res. 63 2003 5838 5843
80. J.W. Kim, and H.S. Lee Tumor targeting by doxorubicin-RGD-4C peptide conjugate in an orthotopic mouse hepatoma model Int. J. Mol. Med. 14 2004 529 535
81. X. Chen, C. Plasencia, Y. Hou, and N. Neamati Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery J. Med. Chem. 48 2005 1098 1106
82. T.J. Wickham, M.E. Carrion, and I. Kovesdi Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifs Gene Ther. 2 1995 750 756
83. I. Dmitriev, V. Krasnykh, C.R. Miller, M. Wang, E. Kashentseva, G. Mikheeva, N. Belousova, and D.T. Curiel An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism J. Virol. 72 1998 9706 9713
84. L. Chen, A.J. Zurita, P.U. Ardelt, R.J. Giordano, W. Arap, and R. Pasqualini Design and validation of a bifunctional ligand display system for receptor targeting Chem. Biol. 11 2004 1081 1091
85. M. Grifman, M. Trepel, P. Speece, L.B. Gilbert, W. Arap, R. Pasqualini, and M.D. Weitzman Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids Mol. Ther. 3 2001 964 975
86. D.J. Burkhart, B.T. Kalet, M.P. Coleman, G.C. Post, and T.H. Koch Doxorubicin-formaldehyde conjugates targeting alphavbeta3 integrin Mol. Cancer Ther. 3 2004 1593 1604
87. Z.F. Su, G. Liu, S. Gupta, Z. Zhu, M. Rusckowski, and D.J. Hnatowich In vitro and in vivo evaluation of a Technetium-99m-labeled cyclic RGD peptide as a specific marker of alpha(V)beta(3) integrin for tumor imaging Bioconjug. Chem. 13 2002 561 570
88. S. Zitzmann, V. Ehemann, and M. Schwab Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo Cancer Res. 62 2002 5139 5143
89. A. Fahr, K. Muller, T. Nahde, R. Muller, and S. Brusselbach A new colloidal lipidic system for gene therapy J. Liposome Res. 12 2002 37 44
90. S.J. DeNardo, P.A. Burke, B.R. Leigh, R.T. O'Donnell, L.A. Miers, L.A. Kroger, S.L. Goodman, S. Matzku, A. Jonczyk, and K.R. Lamborn Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy Cancer Biother. Radiopharm. 15 2000 71 79
91. P.A. Burke, S.J. DeNardo, L.A. Miers, K.R. Lamborn, S. Matzku, and G.L. DeNardo Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts Cancer Res. 62 2002 4263 4272
92. J.W. Smith Cilengitide Merck Curr. Opin. Investig. Drugs 4 2003 741 745
93. K.K. Kim, R. Kim, and S.H. Kim Crystal structure of a small heat-shock protein Nature 394 1998 595 599
94. C.K. Kim, and S.J. Lim Recent progress in drug delivery systems for anticancer agents Arch. Pharm. Res. 25 2002 229 239
95. N. Assa-Munt, X. Jia, P. Laakkonen, and E. Ruoslahti Solution structures and integrin binding activities of an RGD peptide with two isomers Biochemistry 40 2001 2373 2378
96. A.G. Gao, F.P. Lindberg, J.M. Dimitry, E.J. Brown, and W.A. Frazier Thrombospondin modulates alpha v beta 3 function through integrin-associated protein J. Cell Biol. 135 1996 533 544
97. J. Hellwage, S. Kuhn, and P.F. Zipfel The human complement regulatory factor-H-like protein 1, which represents a truncated form of factor H, displays cell-attachment activity Biochem. J. 326 1997 321 327
98. G.T. Hermanson Bioconjugate Techniques 1996 Academic Press San Diego